Advertisement
U.S. markets closed

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
59.09+0.17 (+0.29%)
At close: 04:00PM EDT
59.95 +0.86 (+1.46%)
After hours: 05:18PM EDT
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,385
4,013
4,737
1,078
0
-
Operating Expense
279,332
226,621
172,619
108,780
74,953
-
Operating Income
-277,947
-222,608
-167,882
-107,702
-74,953
-
Net Non Operating Interest Income Expense
25,352
13,436
4,317
157
991
-
Other Income Expense
-5,945
-5,357
-353
-96
150
-
Pretax Income
-258,540
-214,529
-163,918
-107,641
-73,812
-
Net Income Common Stockholders
-258,540
-214,529
-163,918
-107,641
-73,812
-
Diluted NI Available to Com Stockholders
-258,540
-214,529
-163,918
-107,641
-73,812
-
Basic EPS
-3.64
-3.69
-3.15
-2.80
-2.42
-
Diluted EPS
-3.64
-3.69
-3.15
-2.80
-2.42
-
Basic Average Shares
54,717
58,071
51,982
38,436
30,448
-
Diluted Average Shares
54,717
58,071
51,982
38,436
30,448
-
Total Operating Income as Reported
-277,947
-222,608
-167,882
-107,702
-74,953
-
Total Expenses
279,332
226,621
172,619
108,780
74,953
-
Net Income from Continuing & Discontinued Operation
-258,540
-214,529
-163,918
-107,641
-73,812
-
Normalized Income
-258,540
-214,529
-164,518
-107,641
-73,812
-
Interest Income
25,352
13,436
4,317
157
991
-
Net Interest Income
25,352
13,436
4,317
157
991
-
EBIT
-277,947
-222,608
-167,882
-107,702
-74,953
-
EBITDA
-276,185
-221,510
-166,899
-106,780
-74,005
-
Reconciled Depreciation
1,762
1,098
983
922
948
-
Net Income from Continuing Operation Net Minority Interest
-258,540
-214,529
-163,918
-107,641
-73,812
-
Total Unusual Items Excluding Goodwill
-
-
600
-
-
-
Total Unusual Items
-
-
600
-
-
-
Normalized EBITDA
-276,185
-221,510
-167,499
-106,780
-74,005
-
Tax Rate for Calcs
0
0
0
0
0
-
Tax Effect of Unusual Items
0
0
0
0
0
-